Postpartum hemorrhage is the leading cause of maternal mortality worldwide. It is a complication affecting approximately 5% of all deliveries and the cause of nearly 12% of maternal deaths in the United States. ACOG lists uterotonic agents as the first line treatment for postpartum hemorrhage secondary to uterine atony. When a hemorrhage cannot be controlled with uterotonics and uterine massage, use of an intrauterine compression device is recommended. Some studies have shown that there may be a decrease in blood loss and the need for massive transfusion following implementation of a vacuum induced hemorrhage control device, otherwise known as the Jada System. This device was incorporated into routine use on the labor and delivery unit at the University of Oklahoma in the fall of 2023.

A retrospective chart review will be conducted on patients who delivered at the University of Oklahoma who experienced a postpartum hemorrhage. This study will aim to compare hemorrhage data from January – December 2022, prior to the implementation of the Jada device, to data from January-December 2024, following its implementation on labor and delivery. It will seek to identify any statistically significant difference in blood transfusion and uterotonic administration rates following the introduction of vacuum induced hemorrhage control.

Inclusion criteria:

• Any patient who had a vaginal or cesarean delivery who experienced a postpartum hemorrhage with an estimated blood loss greater than or equal to 1000mL
• Hemorrhage must have occurred within the same hospitalization as delivery
• Patients who required a hysterectomy in the setting of uterine atony

Exclusion criteria:

• Patients who had hemorrhages that involved utilization of both an intrauterine balloon tamponade device (Bakri) and a vacuum induced hemorrhage control device (Jada)
• Delayed postpartum hemorrhage following hospital discharge (i.e. readmission for hemorrhage in the setting of retained POC)
• Patients who delivered via cesarean hysterectomy in the setting of placenta accreta spectrum

Primary outcome:

• Number of units of blood transfused as a result hemorrhage
• Number of uterotonics administered during management of postpartum hemorrhage

Data collection ongoing